Related references
Note: Only part of the references are listed.Importance of Shrinkage in Empirical Bayes Estimates for Diagnostics: Problems and Solutions
Radojka M. Savic et al.
AAPS JOURNAL (2009)
Evidence for oxazepam as an in vivo probe of UGT2B15: oxazepam clearance is reduced by UGT2B15 D85Y polymorphism but unaffected by UGT2B17 deletion
Xi He et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2009)
CYP2C19*2 polymorphism is not the sole determinant of the response to clopidogrel: implications for its monitoring
B. Aleil et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2009)
Cytochrome P-450 Polymorphisms and Response to Clopidogrel.
Jessica L. Mega et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
4th US FDA-Drug Information Association pharmacogenomics workshop, held 10-12 December, 2007
Felix W. Frueh et al.
PHARMACOGENOMICS (2009)
Mechanism-based concepts of size and maturity in pharmacokinetics
B. J. Anderson et al.
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY (2008)
Extensions to the Visual Predictive Check to facilitate model performance evaluation
Teun M. Post et al.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2008)
Population pharmacokinetics and proton pump inhibitory effects of intravenous lansoprazole in healthy Japanese males
Yuichi Sakurai et al.
BIOLOGICAL & PHARMACEUTICAL BULLETIN (2007)
Gliptins: a new class of oral hypoglycaemic agent
H. Chahal et al.
QJM-AN INTERNATIONAL JOURNAL OF MEDICINE (2007)
The impact of UGT1A8, UGT1A9, and UGT2B7 genetic polymorphisms on the pharmacokinetic profile of mycophenolic acid after a single oral dose in healthy volunteers
E. Levesque et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2007)
Effect of CYP2C19 genetic polymorphism on pharmacokinetics of phenytoin and phenobarbital in Japanese epileptic patients using Non-linear Mixed Effects Model approach
E. Yukawa et al.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2006)
Effect of CYP2C9 genetic polymorphisms on the efficacy and pharmacokinetics of glimepiride in subjecs with type 2 diabetes
Kazuko Suzuki et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2006)
Pharmacogenetics, drug-metabolizing enzymes, and clinical practice
Sharon J. Gardiner et al.
PHARMACOLOGICAL REVIEWS (2006)
Evaluation of interethnic differences in repinotan pharmacokinetics by using population approach
Takahiko Tanigawa et al.
DRUG METABOLISM AND PHARMACOKINETICS (2006)
Effect of the UGT2B15 genotype on the pharmacokinetics, pharmacodynamics, and drug interactions of intravenous lorazepam in healthy volunteers
JY Chung et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2005)
Pharmacogenomics of human UDP-glucuronosyltransferase enzymes
C Guillemette
PHARMACOGENOMICS JOURNAL (2003)
Assessment of actual significance levels for covariate effects in NONMEM
U Wählby et al.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2001)
Share Paper
